106 related articles for article (PubMed ID: 3002419)
1. Effects of dydrogesterone on the oestrogenized postmenopausal endometrium.
Lane G; Siddle NC; Ryder TA; Pryse-Davies J; King RJ; Whitehead MI
Br J Obstet Gynaecol; 1986 Jan; 93(1):55-62. PubMed ID: 3002419
[TBL] [Abstract][Full Text] [Related]
2. Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium.
Lane G; Siddle NC; Ryder TA; Pryse-Davies J; King RJ; Whitehead MI
Br Med J (Clin Res Ed); 1983 Oct; 287(6401):1241-5. PubMed ID: 6315123
[TBL] [Abstract][Full Text] [Related]
3. Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone.
Siddle NC; Fraser D; Whitehead MI; Jesinger DK; Endacott J; Prescott P; Pryse-Davies J
Br J Obstet Gynaecol; 1990 Dec; 97(12):1101-7. PubMed ID: 2177648
[TBL] [Abstract][Full Text] [Related]
4. Is Provera the ideal progestogen for addition to postmenopausal estrogen therapy?
Lane G; Siddle NC; Ryder TA; Pryse-Davies J; King RJ; Whitehead MI
Fertil Steril; 1986 Mar; 45(3):345-52. PubMed ID: 3005052
[TBL] [Abstract][Full Text] [Related]
5. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium.
Schindler AE
Maturitas; 2009 Dec; 65 Suppl 1():S3-11. PubMed ID: 19969432
[TBL] [Abstract][Full Text] [Related]
6. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium.
Whitehead MI; Townsend PT; Pryse-Davies J; Ryder TA; King RJ
N Engl J Med; 1981 Dec; 305(27):1599-605. PubMed ID: 7312007
[TBL] [Abstract][Full Text] [Related]
7. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17 beta oestradiol.
Burch DJ; Spowart KJ; Jesinger DK; Randall S; Smith SK
Br J Obstet Gynaecol; 1995 Mar; 102(3):243-8. PubMed ID: 7794851
[TBL] [Abstract][Full Text] [Related]
8. Endometrial safety of continuous combined hormone replacement therapy with 17beta-oestradiol (1 or 2 mg) and dydrogesterone.
Bergeron C; Ferenczy A
Maturitas; 2001 Jan; 37(3):191-9. PubMed ID: 11173181
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent effects of synthetic progestins on the biochemistry of the estrogenized post-menopausal endometrium.
Siddle NC; Townsend PT; Young O; Minardi J; King RJ; Whitehead MI
Acta Obstet Gynecol Scand Suppl; 1981; 106():17-22. PubMed ID: 6281330
[TBL] [Abstract][Full Text] [Related]
10. Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone.
Ferenczy A; Gelfand MM
Maturitas; 1997 Apr; 26(3):219-26. PubMed ID: 9147354
[TBL] [Abstract][Full Text] [Related]
11. Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone.
van de Weijer PH; Scholten PC; van der Mooren MJ; Barentsen R; Kenemans P
Climacteric; 1999 Jun; 2(2):101-9. PubMed ID: 11910662
[TBL] [Abstract][Full Text] [Related]
12. Changes in the withdrawal bleeding pattern and endometrial histology during 17 beta-estradiol-dydrogesterone therapy in postmenopausal women: a 2 year prospective study.
van der Mooren MJ; Hanselaar AG; Borm GF; Rolland R
Maturitas; 1994 Dec; 20(2-3):175-80. PubMed ID: 7715470
[TBL] [Abstract][Full Text] [Related]
13. Effect of long-term therapy with estrogen and progesterone on the endometrium of post-menopausal women.
Varma TR
Acta Obstet Gynecol Scand; 1985; 64(1):41-6. PubMed ID: 2983513
[TBL] [Abstract][Full Text] [Related]
14. Effect on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone.
Siddle NC; Jesinger DK; Whitehead MI; Turner P; Lewis B; Prescott P
Br J Obstet Gynaecol; 1990 Dec; 97(12):1093-100. PubMed ID: 2177647
[TBL] [Abstract][Full Text] [Related]
15. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone.
Ferenczy A; Gelfand MM; van de Weijer PH; Rioux JE
Climacteric; 2002 Mar; 5(1):26-35. PubMed ID: 11974556
[TBL] [Abstract][Full Text] [Related]
16. A first study to compare two dosages of dydrogesterone in opposing the 50 mg oestradiol implant.
Rees M; Leather A; Pryse-Davies J; Collins SA; Barlow DH; Studd JW
Maturitas; 1991 Dec; 14(1):9-15. PubMed ID: 1791775
[TBL] [Abstract][Full Text] [Related]
17. Ultra low dose continuous combined hormone replacement therapy with 0.5mg 17beta-oestradiol and 2.5mg dydrogesterone: protection of the endometrium and amenorrhoea rate.
Bergeron C; Nogales FF; Rechberger T; Tatarchjuk T; Zipfel L
Maturitas; 2010 Jun; 66(2):201-5. PubMed ID: 20378287
[TBL] [Abstract][Full Text] [Related]
18. Biochemical studies on endometrium from postmenopausal women receiving hormone replacement therapy.
King RJ; Whitehead MI; Campbell S; Minardi J
Postgrad Med J; 1978; 54 Suppl 2():65-8. PubMed ID: 216982
[TBL] [Abstract][Full Text] [Related]
19. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
Cieraad D; Conradt C; Jesinger D; Bakowski M
Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367
[TBL] [Abstract][Full Text] [Related]
20. Oestradiol: the predominant intranuclear oestrogen in the endometrium of oestrogen-treated postmenopausal women.
Whitehead MI; Lane G; Dyer G; Townsend PT; Collins WP; King RJ
Br J Obstet Gynaecol; 1981 Sep; 88(9):914-8. PubMed ID: 7272264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
